These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 34216176)

  • 1. Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer.
    Gray J; Thompson JC; Carpenter EL; Elkhouly E; Aggarwal C
    Oncologist; 2021 Oct; 26(10):e1812-e1821. PubMed ID: 34216176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLC.
    Cheng ML; Milan MSD; Tamen RM; Bertram AA; Michael KS; Ricciuti B; Kehl KL; Awad MM; Sholl LM; Paweletz CP; Jänne PA
    JCO Precis Oncol; 2021 Nov; 5():726-732. PubMed ID: 34994618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non-Small Cell Lung Cancer (LC-SCRUM-Liquid).
    Sugimoto A; Matsumoto S; Udagawa H; Itotani R; Usui Y; Umemura S; Nishino K; Nakachi I; Kuyama S; Daga H; Hara S; Miyamoto S; Kato T; Sakakibara-Konishi J; Tabata E; Nakagawa T; Kawaguchi T; Sakai T; Shibata Y; Izumi H; Nosaki K; Zenke Y; Yoh K; Goto K
    Clin Cancer Res; 2023 Apr; 29(8):1506-1514. PubMed ID: 36201167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Sensitivity of Plasma Cell-Free DNA Genotyping in Cases With Evidence of Adequate Tumor Content.
    Meador CB; Milan MSD; Hu EY; Awad MM; Rabin MS; Paweletz CP; Hartmaier R; Laus G; Oxnard GR
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
    Shields MD; Chen K; Dutcher G; Patel I; Pellini B
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC.
    Wu Z; Yang Z; Li CS; Zhao W; Liang ZX; Dai Y; Zhu Q; Miao KL; Cui DH; Chen LA
    Cancer Med; 2019 Mar; 8(3):910-919. PubMed ID: 30767431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.
    Li BT; Janku F; Jung B; Hou C; Madwani K; Alden R; Razavi P; Reis-Filho JS; Shen R; Isbell JM; Blocker AW; Eattock N; Gnerre S; Satya RV; Xu H; Zhao C; Hall MP; Hu Y; Sehnert AJ; Brown D; Ladanyi M; Rudin CM; Hunkapiller N; Feeney N; Mills GB; Paweletz CP; Janne PA; Solit DB; Riely GJ; Aravanis A; Oxnard GR
    Ann Oncol; 2019 Apr; 30(4):597-603. PubMed ID: 30891595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
    Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
    Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of circulating free DNA in the management of NSCLC.
    Esposito Abate R; Pasquale R; Fenizia F; Rachiglio AM; Roma C; Bergantino F; Forgione L; Lambiase M; Sacco A; Piccirillo MC; Morabito A; Normanno N
    Expert Rev Anticancer Ther; 2019 Jan; 19(1):19-28. PubMed ID: 30462523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer.
    Page RD; Drusbosky LM; Dada H; Raymond VM; Daniel DB; Divers SG; Reckamp KL; Villalona-Calero MA; Dix D; Odegaard JI; Lanman RB; Papadimitrakopoulou VA; Leighl NB
    Clin Lung Cancer; 2022 Jan; 23(1):72-81. PubMed ID: 34782240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-Step Polymerase Chain Reaction-Free Nanowire-Based Plasma Cell-Free DNA Assay to Detect EML4-ALK Fusion and to Monitor Resistance in Lung Cancer.
    Lee Y; Cho Y; Park EY; Park SY; Hwang KH; Han JY
    Oncologist; 2021 Oct; 26(10):e1683-e1692. PubMed ID: 34272914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
    Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
    Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct profile of cell-free DNA in malignant pleural effusion of non-small cell lung cancer and its impact on clinical genetic testing.
    Yu Y; Qian J; Shen L; Ji W; Lu S
    Int J Med Sci; 2021; 18(6):1510-1518. PubMed ID: 33628109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients.
    Cui W; Milner-Watts C; O'Sullivan H; Lyons H; Minchom A; Bhosle J; Davidson M; Yousaf N; Scott S; Faull I; Kushnir M; Nagy R; O'Brien M; Popat S
    Eur J Cancer; 2022 Aug; 171():44-54. PubMed ID: 35704974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.
    Mayo-de-Las-Casas C; Garzón Ibáñez M; Jordana-Ariza N; García-Peláez B; Balada-Bel A; Villatoro S; Malapelle U; Karachaliou N; Troncone G; Rosell R; Molina-Vila MA
    Expert Rev Mol Diagn; 2018 Jan; 18(1):35-45. PubMed ID: 29172773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liquid biopsy and its role in an advanced clinical trial for lung cancer.
    Johann DJ; Steliga M; Shin IJ; Yoon D; Arnaoutakis K; Hutchins L; Liu M; Liem J; Walker K; Pereira A; Yang M; Jeffus SK; Peterson E; Xu J
    Exp Biol Med (Maywood); 2018 Feb; 243(3):262-271. PubMed ID: 29405770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.
    Tu HY; Li YS; Bai XY; Sun YL; Zheng MY; Ke EE; Liao RQ; Jiang BY; Lin JX; Huang J; Xu BF; Yang JJ; Zhang XC; Zhou Q; Wang BC; Chen HJ; Tong X; Yu R; Wu X; Zhu D; Wu YL
    Clin Lung Cancer; 2022 Mar; 23(2):135-142. PubMed ID: 34645582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer.
    Palmero R; Taus A; Viteri S; Majem M; Carcereny E; Garde-Noguera J; Felip E; Nadal E; Malfettone A; Sampayo M; Riva F; Nagy RJ; Lanman RB; Faull I; Dix D; Karachaliou N; Rosell R
    JCO Precis Oncol; 2021 Nov; 5():93-102. PubMed ID: 34994593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly sensitive fusion detection using plasma cell-free RNA in non-small-cell lung cancers.
    Hasegawa N; Kohsaka S; Kurokawa K; Shinno Y; Takeda Nakamura I; Ueno T; Kojima S; Kawazu M; Suehara Y; Ishijima M; Goto Y; Kojima Y; Yonemori K; Hayashi T; Saito T; Shukuya T; Takahashi F; Takahashi K; Mano H
    Cancer Sci; 2021 Oct; 112(10):4393-4403. PubMed ID: 34310819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC.
    Yang Y; Shen X; Li R; Shen J; Zhang H; Yu L; Liu B; Wang L
    Oncotarget; 2017 Jul; 8(30):49773-49782. PubMed ID: 28572536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.